Class 4 Medicines Defect Notification: Martindale Pharmaceuticals Ltd, Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150ml, EL(26)A/38
Read and act on the official notice on GOV.UK
Usually minor defects in packaging or other printed materials.
What all four recall classes mean
| Class | Action | The MHRA's definition |
|---|---|---|
| Class 1 | Immediate action | The defect presents a risk of death or disability. |
| Class 2 | Action within 48 hours | The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious. |
| Class 3 | Action within 5 days | The defect is unlikely to cause harm to the patient. |
| Class 4 this notice | Caution in use | Usually minor defects in packaging or other printed materials. |
A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.
In plain English, for the pharmacy team
Why is this relevant to community pharmacy
Clobazam is an epilepsy medicine. This Class 4 medicines defect notification says some cartons of the 5 mg/5 mL and 10 mg/5 mL oral suspension have the wrong linear barcode on the outer packaging. The medicine itself is not affected, but the barcode may matter for stock handling and identification in pharmacy.
What to tell patients
Use your professional judgement for each patient.
- This notice is about a barcode error on the outer box.
- The medicine itself is not affected.
- You do not need to take any action.
- If you have any side effects or questions about your medicine, seek medical advice.
- Any suspected side effects can also be reported through the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme.
What needs to be done
- Pharmacists: note the affected batches listed in the notice. This is a Class 4 medicines defect notification, not a recall.
- Check any stock of Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150 mL against the batches listed in the notice.
- If your pharmacy uses the linear barcode for stock handling, do not use the carton’s linear barcode to identify this product. Use the serialized 2D barcode, which the notice says is correct.
- Be aware that the notice says there is no risk to product quality and the affected batches are not being recalled.
- Keep the notice in mind when supplying or handling stock, especially if barcode scanning is used in the pharmacy.
- Report any suspected adverse reactions via the MHRA Yellow Card scheme if needed.
- Read and act on the official GOV.UK notice.
Pharmshark summary, checked and approved by Chris Dotchin on 2 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.
How this summary was written
An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.
The MHRA's summary
Martindale Pharmaceuticals has informed the MHRA of an error with the linear barcode of some batches of Clobazam 5mg/5mL and 10mg/5mL Oral Suspension 150mL.
Pharmshark guides for this alert
Linked to this alert by Pharmshark. Each guide lists this alert under its title.
Affected batches
As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.
| Batch number | Expiry | Pack size | First distributed |
|---|---|---|---|
| Clobazam Martindale Pharma 5 mg/5 mL Oral Suspension 150ml | |||
| 0162858 | 05/2028 | 1 | 18/08/2026 |
| 0163605 | 07/2028 | 1 | 14/09/2026 |
| Clobazam Martindale Pharma 10 mg/5 mL Oral Suspension 150ml | |||
| 0163858 | 07/2028 | 1 | 14/09/2026 |
MHRA's audience tags: Dispensing GP practices, Pharmacy